SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile shares are facing significant downward pressure following an orbital insertion failure during a Blue Origin launch that resulted in the loss of a satellite. While the community is actively debating the reliability of launch partners and the impact on the companys ambitious deployment roadmap, long-term investors are focused on insurance coverage and existing manufacturing pipelines as key catalysts for a potential rebound.

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is generating intense market attention as traders bet on a short squeeze and potential industry-wide transformation following an executive order from the U.S. government regarding the expedited research and development of psychedelic therapies. The community is heavily focused on the stock's low float, aggressive institutional interest, and the belief that the company's GMP-compliant ibogaine supply chain positions it as a critical player in a rapidly expanding mental health sector.

USA Rare Earth, Inc. is domestic supplier of rare earth magnets and heavy rare earth elements. It is developing a vertically integrated, domestic supply chain for rare earth element magnet production, with a facility in Stillwater, Oklahoma, and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

USA Rare Earth is trending following a massive $2.8 billion acquisition of Serra Verde Group, a move the market views as a strategic play to become a dominant, non-Asian leader in the rare earth supply chain. While investors are debating the impacts of the associated share dilution, community sentiment is largely focused on the company's long-term potential to anchor the Western EV and defense infrastructure.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is gaining momentum as retail investors and the community ramp up activity ahead of the upcoming AACR conference, where new data for the SLS009 platform will be presented. Supporters are actively discussing the potential for a significant price movement driven by heavy call option positioning and large-scale short interest, while long-term investors remain focused on the clinical potential of the GPS pivotal Phase 3 study.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is currently a focal point for investors as the community debates the impact of potential trade enforcement, ongoing industry consolidation rumors, and the CEO's recent strategic maneuvers. While some market participants are optimistic about the company's vertically integrated position and the long-term potential for a POSCO partnership, others are expressing significant caution regarding the company's debt levels and recent insider selling activity.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is gaining significant market attention as traders position for imminent Phase 2b data from its alopecia areata trial, a catalyst that follows a period of positive momentum in its broader autoimmune pipeline. While some community members voice concerns over potential volatility and past management execution, the bullish sentiment remains anchored in the drug's differentiated mechanism of action and the anticipation of a potential settlement or partnership deal involving Eli Lilly.

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing intense market volatility as investors weigh the potential of its AI-driven enterprise tools against fears that generative AI could disrupt its established creative software moat. The stock is currently experiencing significant downward pressure as the community debates whether the recent sell-off represents an irrational disconnect from elite fundamentals or a structural shift in the software landscape.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing significant momentum and investor interest as the community points to strong clinical trial data, the upcoming BLA submission, and a highly undervalued market cap relative to its pipeline potential. Investors are actively discussing the possibility of a buyout or strategic partnership, with many viewing current price levels as an accumulation opportunity ahead of key data catalysts.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is trending as investors react to its role as a key U.S.-based, vertically integrated rare earth producer amidst intensified geopolitical tensions and national security concerns. Community discussion is heavily focused on the company's long-term supply chain importance, its recent appearance on a major television segment, and the broader implications of U.S. government policy supporting domestic critical mineral independence.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is trending as a major play in the psychedelic medicine space following a presidential executive order that fast-tracks federal research and access for treatments like psilocybin. The community is actively debating the potential for an FDA approval breakthrough for the company's leading COMP360 candidate, with many investors closely tracking the regulatory tailwinds alongside sentiment from key institutional backers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>U.S. stock futures pulled back early Monday, cooling off after last week’s record-setting gains.</li><li>Investors are monitoring a renewed flare-up in the Strait of Hormuz, after Iran signaled the critical shipping route would remain restricted amid an ongoing standoff with the U.S.</li><li>Psychedelic stocks catch a policy tailwind around expedited drug approvals for mental health treatment: PBM, DFTX, and CMPS are seeing retail attention.&nbsp;</li></ul>U.S. stock futures were under pressure early Monday, after reaching record highs last week amid&nbsp;easing geopolitical&nbsp;fears in the Middle East. However, tensions are on the rise again after President Donald Trump confirmed the seizure of an Iranian-flagged cargo ship in the Strait of Hormuz, prompting Iran to re-close the vital waterway.Trump threatened to "knock out every power plant" in Iran if a new deal is not reached during upcoming talks in Islamabad this week. Oil-linked stocks such as BATL and EONR are back on the radar following a spike in crude volatility.As of 4:00 a.m. ET on Monday, S&amp;P 500 and Nasdaq futures fell 0.6%, Dow futures slipped 0.7%, and Russell 2000 futures were down 1%.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, remained ‘extremely bullish.’Trending Stocks To WatchPsyence Biomedical (PBM):&nbsp;Retail is piling into this little-known psychedelic supplier following U.S. President Donald Trump’s executive order over the weekend to expedite the review of psychedelic medicines, including ibogaine and psilocybin for PTSD and addiction treatment. Also watch out for&nbsp;Definium Therapeutics (DFTX) and Compass Pathways (CMPS).&nbsp;Marvell (MRVL):&nbsp;Reports suggest that Google is in talks with the firm to design two new AI chips, including a next-generation TPU.&nbsp;AST SpaceMobile (ASTS):&nbsp;The stock fell 14% in early pre-market trading after the company confirmed that its BlueBird-7 satellite, launched on New Glenn 3, was placed in an orbit too low to sustain operations.&nbsp;Fermi LLC (FRMI):&nbsp;The stock cracked 16% in early pre-market trade on Monday following a massive leadership overhaul. Early this morning, Fermi announced a transition from its "start-up" roots to a "scaled enterprise.”Critical Metals Corp. (CRML):&nbsp;Remains on retail radar following the updates for its Tabrez project. Meanwhile, on Sunday, Chairman Tony Sage said in a social media post that, while the geopolitical situation has made shipping logistics "tricky," the company still targets Q2 2026 for operations at its Greenland pilot plant.Eli Lilly (LLY):&nbsp;Reports suggest that the company is in advanced talks to acquire Kelonia Therapeutics for over $2B, a deal that could be announced as early as today.Tesla, Inc (TSLA):&nbsp;The stock is on track for its first positive month this year, ahead of its earnings report this week. Meanwhile, Elon Musk downplayed competitive fears from China’s BYD, framing execution and not competition as the EV maker’s key challenge.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included AEVEX Corp (AVEX), Blackberry (BB), and Nvidia Corp (NVDA).&nbsp;Other Catalysts To WatchOn the economic front, no notable data release is expected.On earnings radar, watch out for quarterly reports from Cleveland-Cliffs Inc (CLF), Nano X Imaging Ltd (NNOX), and Dynex Capital Reit Inc (DX) before the bell. Also, Lion Group Holding Ltd (LGHL), AGNC Investment Corp (AGNC), Lottery.com Inc (SEGG), and Alaska Air Group Inc (ALK) report after market close on Monday.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Fall, Oil Risk Back In Focus After Trump’s Iran Escalation: Why PBM, FRMI, ASTS, BATL Are Keeping Traders Engaged Today

Data from Stocktwits shows that retail positioning has remained ‘bullish’ for SPY and QQQ amid geopolitical instability. 

Equity

Data from Stocktwits shows that retail positioning has remained ‘bullish’ for SPY and QQQ amid geopolitical instability. 


<ul class="summary-bullets"><li>Trump directed the FDA to expedite reviews of psychedelic medicines, including ibogaine, and committed $50 million in funding for clinical research.</li><li>The company recently produced medical-grade ibogaine hydrochloride from an ethically sourced African supply.</li><li>Last month, Psyence exported GMP-compliant psilocybin to Australia for use in a Phase IIb clinical trial.</li></ul>Shares of Psyence Biomedical (PBM) surged over 111% to top premarket gains across U.S. stocks on Monday after U.S. President Donald Trump’s executive order accelerating psychedelic therapy research spotlighted the supply infrastructure behind post-traumatic stress disorder (PTSD) treatments such as ibogaine.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> surged 185% last week, marking its strongest weekly performance in more than two years.<h2 class="st-heading-2">Trump Commits $50M To Psychedelic Research</h2>Over the weekend, Trump signed an executive order directing the U.S. Food and Drug Administration (FDA) to expedite the review of psychedelic medicines including ibogaine, while committing $50 million in federal funding toward related clinical research programs.Speaking at the Oval Office signing ceremony, Trump said emerging psychedelic treatments could have a “tremendous impact” if supported by clinical evidence and highlighted their potential role in addressing serious mental-health conditions affecting veterans.&nbsp;Ibogaine, derived from a shrub native to Central and West Africa, remains classified as a Schedule I substance in the U.S. despite growing interest from veterans’ advocacy groups studying its potential use in treating PTSD.<h2 class="st-heading-2">PBM Manufacturing Strategy In Spotlight</h2>A day before the executive order was signed, Psyence CEO Jody Aufrichtig said, “Ibogaine has emerged as a compound of increasing global interest, particularly for its potential to address complex and treatment-resistant conditions.” He added that expanding regulated clinical research would be essential to improving both patient safety and long-term access to ibogaine-based treatments.Through its investment in PsyLabs, the company has built a Good Manufacturing Practice (GMP)-compliant platform that produces pharma-grade psychedelic compounds, including ibogaine, for use in clinical research and drug-development programs.&nbsp;In January, the company said it produced high-purity ibogaine hydrochloride, a medical-grade form of the compound, from ethically sourced natural supply in Africa. The company had already secured access to high-potency iboga bark and established ibogaine operations in Africa through PsyLabs.Separately, last month, the company exported GMP-compliant psilocybin product NPX-5 to Australia for use in an ongoing Phase IIb clinical trial evaluating treatment for adjustment disorder in patients with cancer receiving palliative care.<h2 class="st-heading-2">How Do Retail Traders Feel About PBM?</h2>On Stocktwits, retail sentiment for PBM has been ‘extremely bullish’&nbsp;for&nbsp;a week amid a whopping 15,100% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/pbm_ss_png_5dfee3c956.webp" alt="pbm ss.png" width="959" height="142"><figcaption>PBM sentiment and message volume as of April 20 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/vvvvvvrebel89130/message/650702832">noted</a> that, “psyense is emphasizing their fully integrated supply chain with GMP Able to produce ibogaine at commercial scale.”<stembedurl>https://stocktwits.com/vvvvvvrebel89130/message/650702832</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/momoneyinfla/message/650678443">said</a>, “Not only is it signed they’re bringing the drug to market in weeks NOT years!!!&nbsp; This is gonna be up 500% on Monday”<stembedurl>https://stocktwits.com/momoneyinfla/message/650678443</stembedurl>PBM stock has declined 65% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dftx-vs-cmps-upside-trump-psychedelic-therapy-push/cZBdGeYRIy0">DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push?</a>

In this photo illustration, the Psyence Biomedical logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Is PBM Stock More Than Doubling Premarket Today?

Through its investment in PsyLabs, the Psyence Biomedical company has built a GMP-compliant platform producing pharmaceutical-grade ibogaine.

Through its investment in PsyLabs, the company has built a GMP-compliant platform producing pharmaceutical-grade ibogaine.

Best Small Cap Stocks To Consider - April 17th

AltC Acquisition, Energy Focus, Critical Metals, Spring Valley Acquisition, Inflection Point Acquisition, Direxion Daily MU Bull 2X Shares, and Psyence Biomedical are the seven Small Cap stocks to...

<ul class="summary-bullets"><li>CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>PBM stock closed more than 100% higher on Thursday, and continued the rally on Friday.</li></ul>Shares of Psyence Biomedical Ltd. (PBM) rallied 42% on Friday on the heels of a report that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.PBM stock is on track to clock its best week in over two years, if gains hold.Psyence CEO Jody Aufrichtig said on Friday that ibogaine has emerged as a compound of “increasing global interest,” adding that, “We welcome efforts to advance structured, evidence-based research that can more clearly define its safety, efficacy, and role in clinical care.”The company also highlighted its strategic investment in Psylabs, a biopharmaceutical company based in Southern Africa which specializes in cultivation, extraction, and production of nature-derived psychedelic Active Pharmaceutical Ingredients.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through PsyLabs as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Upcoming Executive Order</h2>On Thursday, CBS News <a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-session-on-report-of-upcoming-executive-order-on-psychedelic-ibogaine/cZJvrazRIDy">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use, and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week. Following the report, PBM stock closed up over 100% on Thursday, and continued the rally on Friday.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels. According to platform data, retail chatter around the stock has jumped 13% over the past day.<a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has lost about 94% over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/asst-hood-coin-stocks-rally-after-btc-nears-78-k-on-hormuz-reopening/cZJUwQaRIU9">ASST, HOOD, COIN, BMNR Stocks Rally After BTC Nears $78K On Strait Of Hormuz Reopening</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PBM Stock On Track For Best Week In Over 2 Years On Hopes For Upcoming Executive Order To Ease Ibogaine Research

Psyence CEO Jody Aufrichtig said on Friday that ibogaine has emerged as a compound of “increasing global interest” and welcomed efforts to advance its research.

<ul class="summary-bullets"><li>The 10-day ceasefire between Israel and Lebanon has gone into effect, while President Donald Trump struck an optimistic tone on the resolution with Iran.</li><li>Markets are beginning to price in de-escalation in the Middle East, sending crude below $100 and nudging equities higher.</li><li>Netflix slumped on weak guidance, while Nvidia remains under scrutiny amid rising skepticism despite its AI leadership.</li></ul>U.S. stock futures&nbsp;rose early Friday as investors weighed the likelihood of a resolution to the Middle East crisis. A 10-day ceasefire is in effect between Israel and Lebanon.&nbsp;Meanwhile, President Donald Trump on Thursday stated the war in Iran “should be ending pretty soon” and described negotiations as “going along swimmingly,” to reopen the Strait of Hormuz. Both countries are expected to resume peace talks over the weekend. Crude oil prices fell below $100/barrel on easing geopolitical tensions, while defense-linked companies found favor among investors.As of 4:00 a.m. ET on Friday, Dow futures rose 0.3%, S&amp;P 500 futures gained 0.1%, Nasdaq futures were flat, and Russell 2000 futures were up 0.2%.&nbsp;Retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF (SPY)</a>, an exchange-traded fund that tracks the S&amp;P 500 Index, and the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> ETF, which tracks the Nasdaq-100 Index, has flipped to ‘extremely bullish,’ a sharp move from the ‘bearish’ sentiment earlier this week.&nbsp;Trending Stocks To WatchNetflix (NFLX):&nbsp;Shares fell nearly 10% in early pre-market trade following a disappointing forecast and the news that co-founder Reed Hastings will exit the board in June. However, CEO Ted Sarandos highlighted that the company’s cash position remains elevated following the failed bid for Warner Bros.&nbsp;Psyence Biomedical (PBM):&nbsp;The stock is attracting heavy retail attention on reports that the White House is preparing an executive order to support further federal research into the psychedelic compound ibogaine.WeShop Holdings (WSHP):&nbsp;The stock has nearly quadrupled in value over the past five sessions and is on track to log its best&nbsp;weekly performance since late November. Retail interest is surging ahead of its results, which are due later this month.&nbsp;Nvidia (NVDA):&nbsp;The AI giant remained under scrutiny after ‘The Big Short’ investor Michael Burry criticized CEO Jensen Huang’s recent podcast appearance. Burry claimed that Huang ‘squirmed and obfuscated’ when questioned about the company’s long-term moat and geopolitical risks.Hims &amp; Hers Health (HIMS):&nbsp;Shares have been gaining attention this week, with new signals from the U.S. Food and Drug Administration (FDA) suggesting that its testosterone therapy could be the next growth driver for this telehealth firm.Defense IPO Watch:&nbsp;Drone maker AEVEX (AVEX) raised $320 million in its IPO, pricing at $20 per share, and is set to debut on the NYSE today. Meanwhile, Arxis (ARXS) soared 36% in its Nasdaq debut on Thursday.AST SpaceMobile (ASTS)&nbsp;has confirmed the BlueBird 7 launch for Sunday, April 19.Other tickers trending on&nbsp;Stocktwits&nbsp;at the time of writing included Verizon (VZ), Iren Limited (IREN), Sidus Space (SIDU), and Rumble Inc (RUM).&nbsp;Other Catalysts To WatchOn the economic front, no notable data release is expected. Traders will be watching commentary from a host of Fed speakers throughout the day, including Richmond Fed President Tom Barkin and Fed Governor Christopher Waller.&nbsp;On earnings radar, watch out for quarterly reports from&nbsp;Fifth Third Bancorp (FITB), State Street (STT), Regions Financial (RF), Ally Financial (ALLY), Truist (TFC), and reAlpha Tech Corp (AIRE), among others, today.For updates and corrections, email newsroom[at]stocktwits[dot]com

Nasdaq, S&P 500 Futures Rise With ‘War Trade’ Unwinding: Why NFLX, WSHP, PBM, HIMS, NVDA Are Keeping Traders Engaged Today

Data from Stocktwits shows that retail positioning has shifted decisively from bearish sentiment earlier this week for SPY and QQQ. 

<ul class="summary-bullets"><li>Trump confirmed a 10-day Israel-Lebanon ceasefire and after saying earlier this week that the Iran war is “very close to over.”</li><li>Markets also reacted to cooler-than-expected producer and import price data and lower-than-forecast jobless claims.</li><li>West Texas Intermediate crude traded near $93 per barrel late Thursday, down more than 3% for the week, while Brent settled above $99.&nbsp;</li></ul>U.S. stock futures traded higher late Thursday after the S&amp;P 500 and Nasdaq closed at fresh record highs earlier in the session, with investors weighing Middle East ceasefire developments alongside improving signs of inflation.As of 9 p.m. ET, Nasdaq 100 and S&amp;P 500 futures were up 0.1%, while Dow futures were up 0.2%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a>,&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a>, and the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘bullish’ amid ‘normal’ message volume.<h2 class="st-heading-2">US Market Drivers</h2>On Thursday, U.S. President Donald Trump confirmed that Israel and Lebanon agreed to a 10-day ceasefire following meetings in Washington. The temporary truce is scheduled to begin at 5 p.m. ET on Thursday.Earlier this week, Trump also said the Iran war is “very close to over” and that Tehran wants to “make a deal very badly.” He added on Thursday that the next round of in-person negotiations could occur next weekend. Optimism around a possible resolution to the conflict helped equities erase losses tied to the war this week.&nbsp;Sentiment was also lifted by cooler-than-expected producer and import price data, along with initial jobless claims for the week ending April 11 that came in below forecasts.Meanwhile, West Texas Intermediate crude traded near $93 per barrel late Thursday, down more than 3% for the week, while Brent&nbsp;hovered above $99. The conflict, which began in February, disrupted traffic through the Strait of Hormuz and affected one-fifth of global oil flows.Despite improving sentiment this week, some Gulf Arab and European leaders said a full U.S.-Iran peace agreement could take about six months to finalize even if the current ceasefire holds, according to a Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-04-16/us-iran-deal-will-take-months-gulf-and-european-officials-say">report</a>.The S&amp;P 500 and Nasdaq Composite both closed at fresh intraday and record closing highs on Thursday, with the Nasdaq extending its winning streak to 12 consecutive sessions, its longest since 2009. All three indexes are on track for weekly gains.<div><figure class="table"><table class="ck-table-resized"><colgroup><col><col><col></colgroup><tbody><tr><td>Index</td><td>Move</td><td>Close</td></tr><tr><td>Dow Jones Industrial Average</td><td>0.24%</td><td>48,578.72</td></tr><tr><td>S&amp;P 500</td><td>0.26%</td><td>7,041.28</td></tr><tr><td>Nasdaq Composite</td><td>0.36%</td><td>24,102.70</td></tr></tbody></table></figure></div>Warren Pies, founder of 3Fourteen Research,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/WarrenPies/status/2044854987377774853">noted on X</a> that the latest all-time high occurred with only 2.4% of S&amp;P 500 stocks making a 52-week high, the lowest participation among 792 such instances since 1998.&nbsp;<h2 class="st-heading-2">Trending Stocks To Watch On NYSE, Nasdaq</h2>Netflix (NFLX): The stock fell 9% in extended trading after the company issued&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nflx-stock-plummets-after-hours-on-outlook-miss-chair-reed-hastings-announces-departure-q1-2026/cZJvDgrRIxR">second-quarter</a> earnings per share (EPS) guidance below Wall Street expectations and said chairman and co-founder Reed Hastings will step down from the board when his term expires in June.Psyence Biomedical (PBM): The stock surged to its best session ever on Thursday and gained another 28% in after-hours trading on&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pbm-stock-on-track-for-best-session-on-report-of-upcoming-executive-order-on-psychedelic-ibogaine/cZJvrazRIDy">reports</a> that the White House is preparing an executive order to support further federal research into the psychedelic compound ibogaine.Avis Budget Group (CAR): The stock climbed to its highest level since November 2021 on Thursday amid elevated short interest and large institutional positions including $4.55 billion held by SRS Investment Management and $2.07 billion by Pentwater Capital, which helped drive a squeeze-supported rally.WeShop Holdings (WSHP): The stock posted its best session in five months ahead of quarterly results expected later this month after the company amid momentum from its recent partnership with CAA Executive Search to build out its U.S. leadership team as part of its expansion strategy.AMC Entertainment Holdings (AMC): The stock is in focus after CEO Adam Aron reiterated support for Paramount Skydance’s acquisition of Warner Bros. Discovery, citing commitments to increase film output to at least 30 releases annually and restore 45-day theatrical exclusivity windows that could benefit cinema operators.<h2 class="st-heading-2">How Global Markets Are Performing Today</h2>In broader markets, the yield on the benchmark 10-year U.S. Treasury note was around 4.28%, while gold traded near $4,793 an ounce after heading toward a fourth weekly gain.Asian markets on Friday, with MSCI’s broadest index of Asia-Pacific shares outside Japan rising more than 1% alongside stronger openings in Japan and Australia.Among the catalysts for Friday’s session are remarks from Federal Reserve officials Mary Daly, Tom Barkin, and Christopher Waller.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-bets-big-on-uber-fleet-but-gm-cadillac-is-attracting-real-buyers/cZJUIctRIx5">Lucid Bets Big On Uber Fleet, But GM’s Cadillac Is Attracting Real Buyers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Wall Street bull stands in the financial district near the New York Stock Exchange (NYSE) on November 18, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Dow, S&P 500, Nasdaq Futures Rise Amid Trump Ceasefire Signals In Iran War: Why NFLX, PBM, WSHP, AMC Are On Watch Tonight

The S&P 500 and Nasdaq Composite both closed at fresh intraday and record closing highs on Thursday.

<ul class="summary-bullets"><li>The report, citing sources, said that the federal government is going to look closely at ibogaine’s safety and effectiveness.&nbsp;</li><li>According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans.</li><li>The Trump administration does not intend to reclassify the drug for medical use, instead keeping it a Schedule I drug in the leagues of heroin, the report added.</li></ul>Shares of Psyence Biomedical (PBM) more than doubled on Thursday following media reports that the White House is drafting an executive order that would signal the Trump administration's willingness to further U.S. research into the psychedelic compound called ibogaine.Shares of the company, which is advancing nature-derived psilocybin and ibogaine therapies, traded 141% higher at the time of writing, on track for its best session to date if gains hold.In November, the company said that it has established a sustainable supply of high-potency iboga bark from trusted sourcing channels with deep experience in the iboga trade and treatment field through its strategic partner, PsyLabs, based in Africa, as it prepares for the clinical development of ibogaine for substance use disorders.<h2 class="st-heading-2">Trump’s Upcoming Executive Order</h2>CBS News <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cbsnews.com/news/psychedelic-drug-ibogaine-ptsd-trump-to-sign-executive-order/">reported</a>, citing sources, that the federal government is going to look closely at ibogaine’s safety and effectiveness. However, the Trump administration does not intend to reclassify the drug for medical use, instead keeping it a &nbsp;Schedule I drug in the leagues of heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote that have no acceptable medical use and high potential for abuse.According to the report, President Trump is expected to sign the executive order as soon as this week.Ibogaine is a psychoactive indole alkaloid derived from the West African Tabernanthe iboga shrub. Research into its therapeutic applications for post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and depression is ongoing,According to CBS, the executive order is meant to open the door to federal funding for further research on its effectiveness with PTSD and traumatic brain injuries, especially among veterans, though it is unclear how the government will help facilitate further research.An official told CBS News that medical research into ibogaine is in an early phase, but the administration wants to help determine whether it's "snake oil" or a legitimate treatment.Other companies in the field of psychedelics, including Clearmind Medicine (CMND), AtaiBeckley (ATAI), GH Research (GHRS), and Compass Pathways (CMPS) are also trading higher on the news.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PBM stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘extremely high’ levels.A Stocktwits user noted that PBM stock is subject to “wild swings.”<stembedurl>https://www.stocktwits.com/dippin_stocks/message/650500248</stembedurl>Another user opined that the stock is going to be “highly volatile” but reach double digit.<stembedurl>https://www.stocktwits.com/momoneyinfla/message/650499935</stembedurl><a href="https://stocktwits.com/symbol/PBM">PBM stock</a> has fallen by about 95% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/achv-stock-on-track-for-best-day-in-over-7-years-whats-driving-the-rally/cZJvoz0RIDM">ACHV Stock On Track To For Best Day In Over 7 Years — What’s Driving The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine

CBS News reported on Thursday that President Trump is expected to sign the executive order as soon as this week.

<ul class="summary-bullets"><li>The company had initially set January 20 as the effective date of the reverse stock split, but delayed the move following additional internal review.</li><li>The total outstanding shares have been reduced from about 6.39 million to roughly 1.02 million.</li><li>This is Psyence Biomedical’s second reverse stock split action in eight months, following a 1-for-7.97 split on May 5.</li></ul>Psyence Biomedical (PBM) stock was in the spotlight on Monday morning after its shares began trading on a post-reverse-split basis on the Nasdaq Capital Market on Monday.<a href="https://stocktwits.com/symbol/PBM">PBM shares</a> were up around 60% at the time of writing.The company had initially set January 20 as the effective date of its 1-for-6.25 reverse stock split, but delayed the move following additional internal review.Under the consolidation, each 6.25 existing share will be combined into one share, reducing the total outstanding shares from about 6.39 million to roughly 1.02 million. The reverse split was authorized by shareholders at a special meeting in April 2025, allowing the board to consolidate shares at a ratio of up to 1-for-50.<h2 class="st-heading-2">Second Reverse Split</h2>Following the special meeting, Psyence Biomedical had implemented a 1-for-7.97 split on May 5, 2025, to increase the per-share trading price of its shares to meet Nasdaq’s $1.00 minimum bid price requirement.Earlier this year, Psyence said its board approved a 2026 financial strategy that includes authorization for a potential share repurchase program to preserve capital for key clinical milestones. The company noted that its stock may be undervalued and that share repurchases could increase per-share ownership.Last November, Psyence approved a $3.5 million follow-on investment in PsyLabs, a producer of purified psychedelic active pharmaceutical ingredients. The investment secures PsyLabs’ position as a critical supplier of GMP-grade psilocybin and ibogaine, supporting Psyence’s clinical pipeline.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for PBM on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a session earlier, amid ‘high’ message volumes.<img src="https://news.stocktwits-cdn.com/PBM_jpg_50a47c9349.webp" alt="PBM.jpg">One Stocktwits user expects the stock to double in value.<stembedurl>https://stocktwits.com/johnny6nine/message/643661274</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-hood-stock-falling-today/cZbgrOOR4kk">HOOD Stock Falls To Over 6-Month Lows – Piper Sandler Flags Three Near-Term Risks But Retail Sees Buying Opportunity</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Wilmington, Delaware-based NRx Pharmaceuticals registered the biggest spike in retail message volume among healthcare stocks last week.  | Image source: Getty Images

Why Is PBM Stock Drawing So Much Investor Interest Today?

Psyence Biomedical was in the spotlight after its shares began trading on a post-reverse-split basis, following a 1-for-6.25 consolidation.

NEW YORK – December 9, 2025 – Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psyencebiomed.com/ceo-year-end-letter-to-shareholders">today released a year-end Letter</a> from Chief Executive Officer Jody Aufrichtig, summarizing the Company’s 2025 achievements and outlining its strategic vision for 2026.In his year-end letter to shareholders, Aufrichtig described 2025 as a “turning point” in which Psyence BioMed delivered clinical execution, strengthened global manufacturing ties, and positioned itself at the forefront of the convergence between nature-derived psychedelic therapeutics and longevity science.“We recruited and dosed our first patients in a Phase IIb study. Through a further investment in <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psylabs.life/">PsyLabs</a> we secured our psychedelic compound supply chain and became the only listed company with an investment in sustainable Ibogaine at source in Africa. We commenced studies in the exciting field of Longevity and ended the year debt free with over USD $9 million in cash reserves.”<h3>Clinical Progress and Phase IIb Trial Momentum</h3>Psyence BioMed advanced its Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for the treatment of Adjustment Disorder in palliative care. Multiple patients were dosed across several Australian clinical sites, supported by a partnership with Southern Star Research, one of Australia’s leading clinical research organisations.<h3>Advancing Nature-Derived Manufacturing and Supply Chain Leadership</h3>The Company strengthened its vertical integration through a multi-million-dollar follow-on investment in PsyLabs, securing GMP compliant nature-derived psilocybin and ibogaine supply for current and future programs. Psyence BioMed also announced a breakthrough in high purity ibogaine production, reinforcing its manufacturing advantage.<h3>Regulatory Tailwinds in Australia</h3>Aufrichtig noted the importance of the Australian Therapeutic Goods Administration’s (TGA) public consultation on psilocybin-assisted therapy for existential distress in patients with life-limiting illness – a development closely aligned with the Company’s clinical trial. If approved, the amendment would enable supervised access through the Authorised Prescriber framework and expand the eligible prescriber group to include palliative-care specialists.<img style="height:auto;" src="https://psyencebiomed.com/wp-content/uploads/2024/02/2.jpg" alt="" srcset="https://psyencebiomed.com/wp-content/uploads/2024/02/2-200x70.jpg 200w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-400x140.jpg 400w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-600x210.jpg 600w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-800x280.jpg 800w, https://psyencebiomed.com/wp-content/uploads/2024/02/2-1200x420.jpg 1200w, https://psyencebiomed.com/wp-content/uploads/2024/02/2.jpg 2000w" sizes="100vw" width="2000" height="700"><h3>A Unique Position in Longevity Science</h3>“Psyence BioMed is currently the only publicly listed psychedelics company investing meaningfully in longevity science,” said Aufrichtig. “Our focus is on the emotional, neurobiological, and existential dimensions of aging, and we believe psychedelic-assisted therapy will play a central role in improving healthspan – not just lifespan.”<h3>2026 Outlook</h3>The Company plans to accelerate enrollment in its Phase IIb clinical trial, expand its manufacturing footprint, pursue additional longevity-focused indications, and evaluate strategic partnership opportunities throughout 2026.The full CEO Letter is available <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psyencebiomed.com/ceo-year-end-letter-to-shareholders/">here</a>.<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://psyencebiomed.com/ceo-year-end-letter-to-shareholders/">CEO Letter 2025</a><h3>Forward Looking Statements</h3>This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the progress of the Phase IIb clinical trial, the expansion of the Company’s current and future programs, and the expansion of the Company’s manufacturing capabilities. These forward-looking statements are based on a number of assumptions, including the assumption that there will be no delays in the execution of the Phase IIb clinical trial implementation schedule, the Company will secure the necessary regulatory and other consents required to expand its current and future programs, and that the demand for psychedelic-assisted therapy will continue to increase. There can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Phase IIb trial; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-289285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025 and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science

Psyence BioMed summarized its successful 2025 clinical and supply-chain efforts, positioning for trial expansion and longevity research in 2026.

Others

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the launch of a new psilocybin longevity research initiative in collaboration with leading researchers in South Africa. This program positions Psyence BioMed as the first – and currently the only – publicly listed company to investigate psilocybin’s potential impact on biological markers associated with aging and longevity. A successful trial could redefine human longevity and transform the future of aging.Longevity science is gaining unprecedented global attention, driven by rapidly aging populations, escalating healthcare costs, and the visibility of figures like Bryan Johnson, who has openly explored both psychedelic therapies and longevity optimization. Simultaneously, scientific literature continues to build support for the intersection of psychedelics and aging biology. Recent preclinical research has shown that psilocin, psilocybin’s active metabolite, extended survival in aged mouse models and increased the lifespan of human skin and lung cells by more than 50 per cent (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=fYmoqTfCjBZWcGz8V1JskJhFG_uolRewQpV-bi1RaRsEryoNNMdonMrkWB3SqGWvWg0qhdj3GJWOxsqlXNgRrWQRcRs80DacDb0ArFTFfka8huTHNHeaTVQh9rj0eXMdFTqGcWkE8MdxnKz_E6UtlKazGIOIDwfqrsSKCx7HeD4=">Source</a>). Additional studies suggest psilocybin may modulate cellular aging by reducing oxidative stress, preserving telomere length, enhancing neuroplasticity, and activating key longevity-associated pathways (<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=fYmoqTfCjBZWcGz8V1JskCgz7HXxcl1tb1YSCpMByydkseHXd1kejdDKddRuuLPDK-IWX9sv3MK1GJmyxO84GKjb_CK-05Vpo8Y1eUrWdQHH34IQ1RIem6VnMUkvdHA7XWkMDIaiyS_6wlTKwqI0kviZ_gcQBhSFJPjwmxYN0p6OvPeP6VR4aydoQxv_-JFC">Source</a>).Working closely with an academic neuroscience faculty, Psyence BioMed is developing an accelerated preclinical protocol designed to evaluate whether psilocybin influences biological mechanisms tied to aging. The study will examine biomarkers related to cellular stress, inflammation, mitochondrial function, and behavioural indicators associated with healthspan and lifespan. The Company has commenced the project, with full acceleration anticipated early in the new year following ethics approval.The research will be conducted under the leadership of Dr. Tanya Calvey, PhD, an internationally recognized neuroscientist specializing in translational neuropsychopharmacology. Dr. Calvey’s work bridges human neuroimaging, molecular biology, and neurohistology to explore how psychoactive compounds influence long-term brain health and cellular resilience.“The scientific community is only beginning to uncover the potential links between psychedelics and longevity,” said Dr. Tanya Calvey. “Psilocybin modulates inflammation, neural connectivity, and cellular stress responses – all central to how we understand aging biology. The collaboration with Psyence BioMed enables us to rigorously investigate these mechanisms and generate evidence that could guide future human studies.”Psyence BioMed Chief Executive Officer, Jody Aufrichtig, reinforced the significance of this initiative, particularly within the broader longevity movement.“Longevity is quickly emerging as one of the most important global health frontiers,” said Aufrichtig. “With public influencers like Bryan Johnson elevating longevity science and exploring psychedelic-assisted interventions, there is tremendous interest in understanding how psilocybin may influence biological aging. As the first publicly listed company actively pursuing this research, Psyence BioMed is positioned at the forefront of an entirely new therapeutic arena.This longevity initiative complements Psyence BioMed’s ongoing clinical development programs, including its psilocybin-assisted therapy trial for existential distress in palliative care patients in Australia. Together, these programs advance the Company’s mission to explore the full therapeutic potential of psilocybin and ibogaine across multiple dimensions of human health – from mental wellness to long-term biological wellbeing.About Psyence BioMedPsyence Biomedical Ltd. (Nasdaq: PBM) is one of the few multi-asset, vertically integrated biopharmaceutical companies specializing in psychedelic-based therapeutics. It is the first life sciences biotechnology company focused on developing nature-derived (non-synthetic) psilocybin and ibogaine-based psychedelic medicine to be listed on Nasdaq. We are dedicated to addressing unmet mental health needs. We are committed to an evidence-based approach in developing safe, effective, and FDA-approved nature-derived psychedelic treatments for a broad range of mental health disorders.Contact Information for Psyence Biomedical Ltd. Email: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=XQW2Y0Fa0-FxEjV63NYOwvGdk0cTKvWhozbeHJ0vxO29rFCcfLQstxrPLpBUpNfpzmrd4WxiYpyVt93o5_rum3uQX_s0CpKfLRE-YqYueIU=">ir@psyencebiomed.com</a>&nbsp;&nbsp;&nbsp; Media Inquiries: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=IvKu5Pl-QkcNUcqTqZZulR2XWJNXenfNrThxr5pm_tykE-HvoIlt0QeDeOKiAW0TWyqdn-FnWuBNI9lobyAx6BJP3LgcG7giwPEsRKZ1LgNnPPOWbRVT7BEn6rOJZIaP">media@psyencebiomed.com</a> General Information: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=q_k_pr10fWV3vFgPus8ajT5amCUP9DDYOL32eHu-y8PRIL8081Gb-xBMAOIFsRUJc6PMAK3guPgg2we_vz6cMQCMdbtGTyEVec13-UqEPkk=">info@psyencebiomed.com</a>Investor Contact: Michael Kydd Investor Relations Advisor <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=89WwssPQnVkGaFixvMLmnD8hcHVGC-sEEJew4-H1pRmWVfOMn6ryodmpOS-LnNNfMoRqMFxQPHQpQ4q8nrt0a2dVSxrDzeEA41eu0YkvFFAyJqomB54EkZkOOkFf0UIQ">michael@psyencebiomed.com</a>Forward Looking StatementsThis communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations, and intentions with respect to future operations, products and services; and other statements identified by words such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “believe,” “intend,” “plan,” “projection,” “outlook” or words of similar meaning.Forward-looking statements in this communication include statements regarding the advancement of the Company's clinical development pipeline, the commencement of the anticipated study, and international interest in longevity science. These forward-looking statements are based on a number of assumptions, including the assumption that ongoing and future study results will be positive, definitive agreements governing the anticipated study will be successfully negotiated, finalized, and executed, the Company will obtain all such regulatory approvals as may be required to execute the anticipated study, that interest in longevity science will continue to grow and that the demand for psychedelic-containing products and related therapy will continue to increase. The Company cannot guarantee that the aforementioned agreements will be completed on the expected timeline or at all. Furthermore, there can be no assurance that the Company will continue to maintain compliance with Nasdaq’s continued listing requirements. There are numerous risks and uncertainties that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements.These risks and uncertainties include, among others: (i) delays in the execution of the Company's drug development and clinical trial pipeline; (ii) the ability of Psyence BioMed to maintain the listing of its common shares and warrants on Nasdaq; (iii) volatility in the price of the securities of Psyence BioMed due to a variety of factors, including the recent share consolidation, changes in the competitive and highly regulated industries in which Psyence BioMed operates, variations in performance across competitors, changes in laws and regulations affecting Psyence BioMed’s business and changes in Psyence BioMed’s capital structure. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s final prospectus (File No. 333-298285) filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2025&nbsp; and other documents filed by Psyence BioMed from time to time with the SEC.These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Actual results and future events could differ materially from those anticipated in such statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Except as required by law, Psyence BioMed does not intend to update these forward-looking statements.The Company does not make any medical, treatment or health benefit claims about its proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceutical products. The efficacy of such products has not been confirmed by authorized clinical research. There is no assurance that the use of psilocybin, psilocybin analogues, or other psychedelic compounds or nutraceuticals can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. The Company has not conducted clinical trials for the use of the proposed products. Any references to quality, consistency, efficacy, and safety of potential products do not imply that the Company has verified such in clinical trials or that the Company will complete such trials. If the Company cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the Company’s performance and operations.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program

First publicly listed company to actively investigate psilocybin’s potential impact on longevity

This account has been verified as an official PBM representative.

Verified Account

Psyence BioMed

Bullish continuation

Sideways chop

Fade lower

Full reversal

The market rebounded fast this week — what’s your call for next week?

Stocktwits

Stocktwits Polls

Investors are piling into companies positioned to supply pharmaceutical-grade ibogaine following a federal executive order supporting psychedelic research.

Traders are closely monitoring ultra-low float stocks for signs of aggressive short-squeeze potential amid high trading volumes.

Capital is rotating quickly into related psychedelic and biotech small-caps as traders hunt for the next explosive runner in the sector.

PBM
Psyence Biomedical Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest PBM News

PBMPsyence Biomedical Ltd.